Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Tumor Lysis Syndrome”

27 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 27 results

Post-approval studies (Phase 4)Study completedNCT00563771
What this trial is testing

Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome

Who this might be right for
Hyperuricemia
Sanofi 38
Not applicableStudy completedNCT03098589
What this trial is testing

Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

Who this might be right for
Lymphoma
Celgene 1,149
Not applicableStudy completedNCT00186940
What this trial is testing

Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients

Who this might be right for
LeukemiaLymphomaTumor Lysis Syndrome+1 more
St. Jude Children's Research Hospital 16
Large-scale testing (Phase 3)Study completedNCT01724528
What this trial is testing

Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies

Who this might be right for
Tumor Lysis Syndrome
Menarini Group 346
Large-scale testing (Phase 3)Looking for participantsNCT06428019
What this trial is testing

Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Who this might be right for
Chronic Lymphocytic Leukemia
AbbVie 170
Not applicableStudy completedNCT02922543
What this trial is testing

A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use

Who this might be right for
Multiple Myeloma
Celgene 361
Testing effectiveness (Phase 2)Study completedNCT00445341
What this trial is testing

Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma

Who this might be right for
Lymphoma
National Cancer Institute (NCI) 28
Early research (Phase 1)Ended earlyNCT04214093
What this trial is testing

AZD0466 in Patients With Advanced Hematologic or Solid Tumors

Who this might be right for
Advanced Solid TumorsLymphomaMultiple Myeloma+1 more
AstraZeneca 9
Testing effectiveness (Phase 2)Ended earlyNCT00664144
What this trial is testing

Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma

Who this might be right for
Hyperuricemia
Sanofi 33
Post-approval studies (Phase 4)Study completedNCT00302653
What this trial is testing

Rasburicase in Tumor Lysis Syndrome

Who this might be right for
Hyperuricemia
Sanofi 33
Not applicableStudy completedNCT02921802
What this trial is testing

Special Use Results Surveillance of Revlimid 5mg Capsules

Who this might be right for
Multiple MyelomaMyelodysplastic Syndromes
Celgene 4,626
Testing effectiveness (Phase 2)Study completedNCT00290992
What this trial is testing

Rasburicase for Hyperuricemia

Who this might be right for
Nutritional and Metabolic Diseases
Sanofi 30
Not applicableNot Yet RecruitingNCT07691047
What this trial is testing

Reassessment of the Risk of Hemolytic Syndrome in Patients With Chronic Lymphocytic Leukemia Treated With a Regimen Containing Venetoclax

Who this might be right for
Chronic Lymphoid Leukemia
Private Hospital of Confluent, France 130
Not applicableStudy completedNCT02921828
What this trial is testing

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

Who this might be right for
Multiple Myeloma
Celgene 1,149
Testing effectiveness (Phase 2)Study completedNCT00360438
What this trial is testing

Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS

Who this might be right for
LeukemiaLymphomaTumor Lysis Syndrome
M.D. Anderson Cancer Center 18
Large-scale testing (Phase 3)Study completedNCT03406156
What this trial is testing

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Who this might be right for
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
AbbVie 120
Not applicableLooking for participantsNCT06889974
What this trial is testing

Timing of Renal Replacement Therapy Initiation in Tumor Lysis Syndrome

Who this might be right for
Renal Replacement Therapy for Acute Kidney Injury in ICU
University Hospital, Bordeaux 800
Early research (Phase 1)Looking for participantsNCT06708897
What this trial is testing

Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

Who this might be right for
CLL / SLLCLL (Chronic Lymphocytic Leukemia)SLL (Small Lymphocytic Lymphoma)+2 more
Lomond Therapeutics Holdings, Inc. 84
Not applicableUnknownNCT05840289
What this trial is testing

A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma

Who this might be right for
Aggressive B-Cell Non-Hodgkin Lymphoma
University Hospital, Geneva 94
Not applicableEnded earlyNCT01097369
What this trial is testing

Elitek (Rasburicase) Immuno-Monitoring Study

Who this might be right for
Tumor Lysis Syndrome
Sanofi 1
Next Page